Marco Giallombardo
Overview
Explore the profile of Marco Giallombardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taverna S, Pucci M, Giallombardo M, Di Bella M, Santarpia M, Reclusa P, et al.
Sci Rep
. 2017 Jun;
7(1):3170.
PMID: 28600504
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide. The majority of patients are diagnosed in advanced disease stage. Bone metastasis is the most frequent complication...
2.
Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, et al.
Front Med (Lausanne)
. 2017 Mar;
4:13.
PMID: 28293555
Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new,...
3.
Rolfo C, Giallombardo M, Reclusa P, Sirera R, Peeters M
Lung Cancer
. 2016 Nov;
104:134-135.
PMID: 27894607
No abstract available.
4.
Reclusa P, Sirera R, Araujo A, Giallombardo M, Valentino A, Sorber L, et al.
Transl Lung Cancer Res
. 2016 Nov;
5(5):483-491.
PMID: 27826529
Lung cancer is a highly lethal disease. Targeted therapies have been developed in last years, however survival rates are not improving due to the delay in the diagnosis, making biomarkers...
5.
Giallombardo M, Taverna S, Alessandro R, Hong D, Rolfo C
Ther Adv Med Oncol
. 2016 Sep;
8(5):320-2.
PMID: 27583023
No abstract available.
6.
Giallombardo M, Chacartegui Borras J, Castiglia M, Van Der Steen N, Mertens I, Pauwels P, et al.
J Vis Exp
. 2016 Jun;
(111).
PMID: 27285610
The discovery of alterations in the EGFR and ALK genes, amongst others, in NSCLC has driven the development of targeted-drug therapy using selective tyrosine kinase inhibitors (TKIs). To optimize the...
7.
Taverna S, Fontana S, Monteleone F, Pucci M, Saieva L, De Caro V, et al.
Oncotarget
. 2016 Apr;
7(21):30420-39.
PMID: 27050372
Tumor derived exosomes are vesicles which contain proteins and microRNAs that mediate cell-cell communication and are involved in angiogenesis and tumor progression. Curcumin derived from the plant Curcuma longa, shows...
8.
Caparica R, de Castro Jr G, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, et al.
Crit Rev Oncol Hematol
. 2016 Mar;
101:32-9.
PMID: 26960735
B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth...
9.
Taverna S, Giallombardo M, Gil-Bazo I, Carreca A, Castiglia M, Chacartegui J, et al.
Oncotarget
. 2016 Feb;
7(19):28748-60.
PMID: 26919248
Exosomes are nano-sized vesicles of endolysosomal origin, released by several cytotypes in physiological and pathological conditions. Tumor derived exosomes, interacting with other cells of the tumor microenvironment, modulate tumor progression,...
10.
Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, et al.
Expert Opin Investig Drugs
. 2016 Feb;
25(4):385-92.
PMID: 26881293
Introduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identified in several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potential role as oncogenic drivers...